News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OPGN: Yeah, but NOT these kinds of "LIQUIDS", Dude!! (Film below of ME again, last Saturday, sampling the nasty 'Soup-Du-Jour' at a cheap country club here in San Diego!!!)
excellent,lmao,enjoy all that marine biology,drink plenty of liquids
NOPE!! (Basically, all day today I'm been 'relaxing' in my new Home Depot "HOT(BlondChicks)TUB" --- see me, below.)
power hour soon,those who wanted out,are out,macd oversold>green just crossed to upside,bulls normally follow soon
mid-day vol. surge,all accululation,walkdown was accumulation also,hording going on,its like a buyback!!
did u buy and cause the explosion,its running now 
cancelled the dilutive funding,buyout makes sense,if going bk they would still do bad funding then bk
270k shares short,49% fee,time to cover bitches
eps qq up 63%,demand growing/supply was @.385,thru that as i typed,wow!!!
upticks on few hundred shares,so far letting it go today,all natural accumulation
relative buying vol. up 1576% today,institutional starting ?,insiders know what is coming,8mms stacked wanting shares on this low float
ZERO BORROW,ZERO REBATE,49% short fee,not optionable,started today,no rebate is insanely rare,who in right mind is going to pay 49% to short this down here
|
Followers
|
75
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2719
|
|
Created
|
07/29/15
|
Type
|
Free
|
| Moderators | |||
Vexing problems oftimes lead to creative solutions. OpGen's robust ingenuity is a case in point.
Problem: "Antibiotic resistance is a global threat. There is no system in place to track antibiotic resistance globally. Without urgent action, many modern medicines could become obsolete, turning even common infections into deadly threats." -U.S. Center for Disease Control
Enter OpGen, Inc. Press Releases
OpGen, Inc. (Gaithersburg, MD, USA) (Nasdaq OPGN) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to guide clinicians with rapid and actionable information about life-threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms (MDRO). Subsidiaries include Curetis GmbH and
Ares Genetics GmbH*. Partners include Sandoz, QIAGEN, Merck, HIPS, Curetis, BGI, Max Perutz Labs Vienna, MGI. Learn more
OpGen’s product portfolio includes Unyvero, Acuitas AMR Gene Panel, PNA FISH, Quick Fish, Acuitas® Lighthouse, and the ARES Technology Platform. The Ares Technology Platform includes ARESdb (db=database) that uses NGS (next generation sequencing) technology and AI-powered bioinformatics solutions to predict antibiotic response (resistance). Artificial intelligence based DNA testing revolutionizes infectious disease diagnostics and therapeutics.* Patient outcomes improved; costs reduced. Learn more
"Time is of the essence in cases of severe infections, not infrequently a question of life or death, and knowing what not to prescribe is as important as knowing what to prescribe."
OpGen Corporate Overview 06-Oct-2020 
(Recommended viewing)
*02Oct2020 OpGen's wholly owned Ares Genetics GmbH* (Vienna) won the Austria State Prize for innovation with their Project "ARESupa- Molecular Antibiotic Resistance Diagnostics using Artificial Intelligence - With a (Ares Genetics) universal pathogen test, antibiotic resistance from germs can be predicted quickly and accurately."
OpGen subsidiary Ares Genetics, which combines Next Generation Sequencing (NGS) with ARESdb, is the world‘s most comprehensive database on the genetics of antibiotic resistance. ARESdb is also the world’s largest database of genetic antibiotic resistance markers and predictive AMR panels. ARESdb contains thousands of whole genome sequenced clinical isolates collected from more than 200 centers globally. ARESdb combines broad resistance profiles with high-quality genetic information and enables pathogen identification with up to >99% accuracy and antibiotic resistance detection with ~98% accuracy. ARESdb covers 30 years of emerging antibiotic resistance to accurately detect AMR and combines deep whole-genome sequencing data with antibiotic resistance profiles continuously expanded. Partners include Sandoz, QIAGEN, Merck, HIPS, Curetis, BGI, Max Perutz Labs Vienna, MGI.
Fast & Simple Syndromic Testing for Severe Infections -- Improving Patient Outcomes
Detects pathogens rapidly, including associated antibiotic resistance genes
Antibiotic resistant microorganisms are a global health threat (Per CDC, WHO, US GAO)
Our UNYVERO A50 IS FDA APPROVED UNYVERO FLYER (Recommended viewing)
With the Unyvero A50 Solution, OPGen's wholly owned subsidiary Curetis has developed a molecular diagnostics system for reliable and extremely rapid diagnosis of severe infectious diseases in under 5 hours versus up to 96 hours using current methods. The system uses powerful multiplex PCR technology and syndromic testing to detect a wide variety of microorganisms, antibiotic resistance markers, or toxins.
Unyvero A50 Applications for Major Infectious Disease
HPN- Hospitalized Pneumonia
HPN Solution
BCU — Blood Culture
Analyzes the DNA of 103 pathogens & resistance genes from a
positive blood culture for fast diagnostics of blood stream infections.
BCU Solution
IAI — Intra-Abdominal Infection
IAI Solution
UTI — Urinary Tract Infection
Unyvero A50 System
Unyvero A50 Cartridge
Applications
Unyvero A30 RQ in development
